Ozmosi | EU-103 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

EU-103

Alternative Names: EU-103, EU 103, EU103
Clinical Status: Active
Latest Update: 2024-03-13
Latest Update Note: Clinical Trial Update

Product Description

VSIG4-specific mAb. (Sourced from: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e14516)

Mechanisms of Action: VSIG4 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eutilex
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EU-103

Countries in Clinic: Korea

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05798026

 EU-CTS103-I-01

P1

Recruiting

Oncology Solid Tumor Unspecified

2025-04-30

21%

2024-03-14

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions